| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2009: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Research Abstract |
To evaluate the factors to detect the prognosis of the patients with heart failure, blood samples, clinical factors and medicine were screened. The anti-p53 antibody was not related to the severity of the heart failure. The prescription of telmisartan was related to the inhibitory effects on the progression of intima-media thickness of the carotid artery wall. The prescription of candesartan was related to the inhibitory effects on the morning hypertension, which was one of the risk factors of cardiovascular mortality.
|
